Skip to main content
. 2016 Mar 28;7(18):26496–26515. doi: 10.18632/oncotarget.8420

Figure 3. RIG-I orchestrates the MAVS-dependent Type I interferon response to ionizing radiation.

Figure 3

A. Quantification of IR-induced IFN-beta secretion (left), caspase 3/7 activation (middle), and cell viability using XTT assay (right) in ICR RIG-I+/+ (WT) and RIG-I−/− MEFs 48 hours after IR exposure. B. IFN-beta protein secretion (left) and caspase 3/7 activation (right) 48 hours post-IR treatment following shRNA-mediated suppression of RIG-I (shRIG-I) in D54 cells. shScrambled – scrambled shRNA control. C. Relative tumor growth of shRIG-I D54 tumor xenografts in athymic nude mice treated with IR (5 Gy x 6 daily fractions). shScr – scrambled shRNA control. Data are representative of three experiments, each with n = 5 mice per group. D. Caspase 3/7 activity of RIG-I−/− and WT MEFs in response to increasing doses of cisplatin (left), doxorubicin (middle) and etoposide (right). Data are representative of three independent experiments. P values were determined using unpaired Student's t-test. Error bars are SEM. *P < 0.05, **P < 0.01, ***P < 0.005.